{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:16:38Z","timestamp":1781658998930,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s43441-021-00327-3","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T02:22:21Z","timestamp":1627698141000},"page":"1155-1164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Implementation of a Pregnancy Prevention Programme (PPP) with a Controlled Distribution System (CDS) for the Generic Teratogenic Phthalimides Thalidomide, Lenalidomide and Pomalidomide"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-715X","authenticated-orcid":false,"given":"Marion","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"issue":"7216","key":"327_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","volume":"278","author":"WG McBride","year":"1961","unstructured":"McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;278(7216):1358. https:\/\/doi.org\/10.1016\/S0140-6736(61)90927-8.","journal-title":"Lancet"},{"issue":"7224","key":"327_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0140-6736(62)91248-5","volume":"1","author":"AL Speirs","year":"1962","unstructured":"Speirs AL. Thalidomide and congenital abnormalities. Lancet. 1962;1(7224):303\u20135. https:\/\/doi.org\/10.1016\/s0140-6736(62)91248-5.","journal-title":"Lancet"},{"issue":"2","key":"327_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/s0149-2918(03)80085-1","volume":"25","author":"SJ Matthews","year":"2003","unstructured":"Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther. 2003;25(2):342\u201395. https:\/\/doi.org\/10.1016\/s0149-2918(03)80085-1.","journal-title":"Clin Ther"},{"issue":"1","key":"327_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1517\/14740338.2011.527331","volume":"10","author":"R Bwire","year":"2011","unstructured":"Bwire R, Freeman J, Houn F. Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective. Expert Opin Drug Saf. 2011;10(1):3\u20138. https:\/\/doi.org\/10.1517\/14740338.2011.527331.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"327_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/tera.1420380303","volume":"38","author":"W Lenz","year":"1988","unstructured":"Lenz W. A short history of thalidomide embryopathy. Teratology. 1988;38(3):203\u201315. https:\/\/doi.org\/10.1002\/tera.1420380303.","journal-title":"Teratology"},{"issue":"2","key":"327_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/bdrc.21096","volume":"105","author":"N Vargesson","year":"2015","unstructured":"Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res. 2015;105(2):140\u201356. https:\/\/doi.org\/10.1002\/bdrc.21096.","journal-title":"Birth Defects Res"},{"key":"327_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/B978-0-12-804239-7.00026-3","volume-title":"Reproductive and developmental toxicology","author":"N Vargesson","year":"2017","unstructured":"Vargesson N. Thalidomide. In: Gupta RC, editor. Reproductive and developmental toxicology. 2nd ed. New York: Academic Press; 2017. p. 467\u201379.","edition":"2"},{"issue":"9","key":"327_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/bdra.20384","volume":"79","author":"L Schuler-Faccini","year":"2007","unstructured":"Schuler-Faccini L, Franca Soares RC, Moreira de Sousa AC, Maximino C, Luna E, Doderlein Schwartz IV, et al. New cases of thalidomide embryopathy in Brazil. Birth Defects Res. 2007;79(9):671\u20132. https:\/\/doi.org\/10.1002\/bdra.20384.","journal-title":"Birth Defects Res."},{"key":"327_CR9","unstructured":"World Health Organization, Model List of Essential Medicines, 19th edition. https:\/\/www.who.int\/publications\/i\/item\/WHOMVPEMPIAU2019.06. Accessed 31 Dec 2020"},{"issue":"2","key":"327_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0149-2918(00)88289-2","volume":"21","author":"JB Zeldis","year":"1999","unstructured":"Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999;21(2):319\u201330. https:\/\/doi.org\/10.1016\/s0149-2918(00)88289-2.","journal-title":"Clin Ther."},{"issue":"9","key":"327_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2165\/00002018-200831090-00003","volume":"31","author":"CP Castaneda","year":"2008","unstructured":"Castaneda CP, Zeldis JB, Freeman J, Quigley C, Brandenburg NA, Bwire R. RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide. Drug Saf. 2008;31(9):743\u201352. https:\/\/doi.org\/10.2165\/00002018-200831090-00003.","journal-title":"Drug Saf"},{"key":"327_CR12","volume-title":"Clinical embryology","author":"S Wills","year":"2019","unstructured":"Wills S. Teratogenesis and Infection. In: Carachi R, Doss S, editors. Clinical embryology. Cham: Springer; 2019."},{"issue":"5","key":"327_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/humrep\/dey089","volume":"33","author":"Group ECW","year":"2018","unstructured":"Group ECW. Why after 50 years of effective contraception do we still have unintended pregnancy? A European perspective. Hum Reprod. 2018;33(5):777\u201383. https:\/\/doi.org\/10.1093\/humrep\/dey089.","journal-title":"Hum Reprod"},{"key":"327_CR14","unstructured":"Office of Women\u00b4s Health (USA), Factsheet: Menstruation and the Menstrual Cycle. 2014. https:\/\/web.archive.org\/web\/20150629023922; http:\/\/www.womenshealth.gov\/publications\/our-publications\/fact-sheet\/menstruation.pdf. Accessed 15 Jan 2021"},{"key":"327_CR15","unstructured":"European Medicines Agency, Summary of Product Characteristics_Thalidomide-Celgene. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/thalidomide-celgene-epar-product-information_en.pdf. Accessed 14 Jan 2021"},{"key":"327_CR16","unstructured":"European Medicines Agency, Summary of Product Characteristics_Revlimid. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revlimid-epar-product-information_en.pdf. Accessed 10 Feb 2021"},{"key":"327_CR17","unstructured":"European Medicines Agency, Summary of Product Characteristics_Imnovid. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imnovid-epar-product-information_en.pdf. Accessed 10 Feb 2021"},{"key":"327_CR18","volume-title":"Clinical embryology","author":"SH Doss","year":"2019","unstructured":"Doss SH, Sneddon SF. General embryology. In: Carachi R, Doss S, editors. Clinical embryology. Cham: Springer; 2019."},{"key":"327_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/B978-0-12-804239-7.00006-8","volume-title":"Reproductive and developmental toxicology","author":"RC Garg","year":"2017","unstructured":"Garg RC, Bracken WM, Hoberman AM, Enright B. Tornesi B (2017) Reproductive and developmental safety evaluation of new pharmaceutical compounds. In: Gupta RC, editor. Reproductive and developmental toxicology. 2nd ed. Academic Press: New York; 2017. p. 101\u201327.","edition":"2"},{"key":"327_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/B978-0-12-804239-7.00009-3","volume-title":"Reproductive and developmental toxicology","author":"C Estevan","year":"2017","unstructured":"Estevan C, Pamies D, Vilanova E, Sogorb MA. OECD guidelines for in\u00a0vivo testing of reproductive toxicity. In: Gupta RC, editor. Reproductive and developmental toxicology. 2nd ed. Academic Press: New York; 2017. p. 163\u201378.","edition":"2"},{"issue":"2","key":"327_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","volume":"32","author":"T Tomson","year":"2019","unstructured":"Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32(2):246\u201352. https:\/\/doi.org\/10.1097\/WCO.0000000000000659.","journal-title":"Curr Opin Neurol"},{"key":"327_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.reprotox.2015.03.007","volume":"53","author":"F Sales Luiz Vianna","year":"2015","unstructured":"Sales Luiz Vianna F, de Oliveira MZ, Sanseverino MTV, Morelo EF, de Lyra Rabello Neto D, Lopez-Camelo J, et al. Pharmacoepidemiology and thalidomide embryopathy surveillance in Brazil. Reprod Toxicol. 2015;53:63\u20137. https:\/\/doi.org\/10.1016\/j.reprotox.2015.03.007.","journal-title":"Reprod Toxicol."},{"issue":"1","key":"327_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejmg.2016.09.015","volume":"60","author":"F Sales Luiz Vianna","year":"2017","unstructured":"Sales Luiz Vianna F, Kowalski TW, Fraga LR, Sanseverino MT, Schuler-Faccini L. The impact of thalidomide use in birth defects in Brazil. Eur J Med Genet. 2017;60(1):12\u20135. https:\/\/doi.org\/10.1016\/j.ejmg.2016.09.015.","journal-title":"Eur J Med Genet."},{"key":"327_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/978-1-62703-131-8_36","volume":"947","author":"JE Ridings","year":"2013","unstructured":"Ridings JE. The thalidomide disaster, lessons from the past. Methods Mol Biol. 2013;947:575\u201386. https:\/\/doi.org\/10.1007\/978-1-62703-131-8_36.","journal-title":"Methods Mol Biol"},{"key":"327_CR25","unstructured":"World Health Organization, Factsheets, Leprosy. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leprosy. Accessed 19 Feb 2021."},{"issue":"7","key":"327_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaoncol.2018.0808","volume":"4","author":"YT Yang","year":"2018","unstructured":"Yang YT, Chen B, Bennett CL. Thalidomide, drug safety, and off-label prescribing: lessons learned from Celgene\u2019s settlement. JAMA Oncol. 2018;4(7):915\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0808.","journal-title":"JAMA Oncol"},{"key":"327_CR27","unstructured":"Pan American Health Organization, The importance of pharmacovigilance. 2002. www.paho.org. Accessed 31 Dec 2020"},{"key":"327_CR28","unstructured":"European Medicines Agency, Guideline on Good Pharmacovigilance Practices (GVP). Module XVI. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools_en-3.pdf. Accessed 15 Jan 2021"},{"issue":"4","key":"327_CR29","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/10428194.2017.1361030","volume":"59","author":"C Castaneda","year":"2018","unstructured":"Castaneda C, Minton N, Mezo M, Hirsch D, Phillips L, Sheehan P, et al. False-positive pregnancy tests in females of reproductive potential receiving lenalidomide in the United States. Leuk Lymphoma. 2018;59(4):1025\u20136. https:\/\/doi.org\/10.1080\/10428194.2017.1361030.","journal-title":"Leuk Lymphoma"},{"key":"327_CR30","unstructured":"European Medicines Agency., Revlimid: EPAR - Risk-management-plan summary. https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/revlimid-epar-risk-management-plan-summary_en.pdf. Accessed 06 Jan 2020"},{"key":"327_CR31","unstructured":"European Medicines Agency, Thalidomide Celgene: EPAR - Risk Management Plan Summary. https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/thalidomide-celgene-epar-risk-management-plan-summary_en.pdf. Accessed 06 Jan 2021"},{"key":"327_CR32","unstructured":"European Medicines Agency, Imnovid: EPAR - Risk-management-plan summary. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imnovid. Accessed 06 Jan 2021"},{"key":"327_CR33","unstructured":"Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/search_product.cfm. Accessed 06 Jan 2021"},{"issue":"10","key":"327_CR34","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1108\/09600031211281411","volume":"42","author":"A Wieland","year":"2012","unstructured":"Wieland A, Marcus WC. Dealing with supply chain risks: Linking risk management practices and strategies to performance. Int J Phys Distrib Logist Manag. 2012;42(10):887\u2013905. https:\/\/doi.org\/10.1108\/09600031211281411.","journal-title":"Int J Phys Distrib Logist Manag"},{"key":"327_CR35","unstructured":"CT. EU Clinical Trial Register. https:\/\/www.clinicaltrialsregister.eu\/. Accessed 06 Jan 2021."},{"issue":"6787","key":"327_CR36","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/bmj.302.6787.1276-b","volume":"302","author":"RM Noyelle","year":"1991","unstructured":"Noyelle RM. No blood, no drug. BMJ. 1991;302(6787):1276. https:\/\/doi.org\/10.1136\/bmj.302.6787.1276-b.","journal-title":"BMJ"},{"key":"327_CR37","unstructured":"Addressing Challenges in Access to Oncology Medicines. Health Division, OECD Directorate for Employment, Labour and Social Affairs. https:\/\/www.oecd.org\/health\/health-systems\/addressing-challenges-in-access-to-oncology-medicines.htm. Accessed 10 Feb 2021"},{"key":"327_CR38","unstructured":"Federal Institue for drugs and Medical Devices, T-Prescriptions. https:\/\/www.bfarm.de\/EN\/FederalOpiumAgency\/T-Prescriptions\/_node.html. Accessed 19 Jan 2021"},{"issue":"2","key":"327_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.18549\/PharmPract.2016.02.702","volume":"14","author":"T Hammar","year":"2016","unstructured":"Hammar T, Nilsson AL, Hovstadius B. Patients\u2019 views on electronic patient information leaflets. Pharm Pract (Granada). 2016;14(2):702. https:\/\/doi.org\/10.18549\/PharmPract.2016.02.702.","journal-title":"Pharm Pract (Granada)"},{"issue":"8","key":"327_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008329","volume":"14","author":"SM Jesus","year":"2020","unstructured":"Jesus SM, Santana RS, Leite SN. The organization, weaknesses, and challenges of the control of thalidomide in Brazil: A review. PLoS Negl Trop Dis. 2020;14(8): e0008329. https:\/\/doi.org\/10.1371\/journal.pntd.0008329.","journal-title":"PLoS Negl Trop Dis"},{"key":"327_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2019-010588","author":"J Zipursky","year":"2020","unstructured":"Zipursky J. REMS in pregnancy: System perfectly designed to the get the results it gets. BMJ Qual Saf. 2020. https:\/\/doi.org\/10.1136\/bmjqs-2019-010588.","journal-title":"BMJ Qual Saf"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-021-00327-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-021-00327-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-021-00327-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T01:27:16Z","timestamp":1633483636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-021-00327-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1007\/s43441-021-00327-3","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"10 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors work for different departments of a pharmaceutical company undertaking work related to the content of the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}